Ocugen Inc

NASDAQ:OCGN  
2.50
-0.04 (-1.58%)
Products

Ocugen Says FDA Removes Clinical Hold On Phase 2/3 Clinical Trial For Covaxin

Published: 05/23/2022 11:53 GMT
Ocugen Inc (OCGN) - Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for Covaxin™ (bbv152).
Ocugen Inc - U.S. Food and Drug Administration (fda) Lifted Clinical Hold on Company's Phase 2/3 Clinical Trial, Ocu-002, for Covaxin™ (bbv152).
Ocugen Inc - Will Now Work With Study Sites to Fully Resume This Clinical Development Program Immediately.